These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 19022363)

  • 1. Pharmacogenomic approaches in clinical studies to identify biomarkers of safety and efficacy.
    Burczynski ME
    Toxicol Lett; 2009 Apr; 186(1):18-21. PubMed ID: 19022363
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Toxicogenomics in predictive toxicology in drug development.
    Suter L; Babiss LE; Wheeldon EB
    Chem Biol; 2004 Feb; 11(2):161-71. PubMed ID: 15123278
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An FDA perspective on the nonclinical use of the X-Omics technologies and the safety of new drugs.
    Jacobs A
    Toxicol Lett; 2009 Apr; 186(1):32-5. PubMed ID: 18809476
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Toxicogenomics in drug discovery: from preclinical studies to clinical trials.
    Yang Y; Blomme EA; Waring JF
    Chem Biol Interact; 2004 Nov; 150(1):71-85. PubMed ID: 15522262
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biomarkers: a valuable tool in clinical research and medical practice.
    Carini C
    IDrugs; 2007 Jun; 10(6):395-8. PubMed ID: 17642003
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Strategic applications of toxicogenomics in early drug discovery.
    Ryan TP; Stevens JL; Thomas CE
    Curr Opin Pharmacol; 2008 Oct; 8(5):654-60. PubMed ID: 18760379
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Japanese toxicogenomics project: application of toxicogenomics.
    Uehara T; Ono A; Maruyama T; Kato I; Yamada H; Ohno Y; Urushidani T
    Mol Nutr Food Res; 2010 Feb; 54(2):218-27. PubMed ID: 20041446
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Toxicogenomics and clinical toxicology: an example of the connection between basic and applied sciences.
    Ferrer-Dufol A; Menao-Guillen S
    Toxicol Lett; 2009 Apr; 186(1):2-8. PubMed ID: 19027838
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A holistic strategy for characterizing the safety of metabolites through drug discovery and development.
    Walker D; Brady J; Dalvie D; Davis J; Dowty M; Duncan JN; Nedderman A; Obach RS; Wright P
    Chem Res Toxicol; 2009 Oct; 22(10):1653-62. PubMed ID: 19715349
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The state-of-the-art in predictive toxicogenomics.
    Fielden MR; Kolaja KL
    Curr Opin Drug Discov Devel; 2006 Jan; 9(1):84-91. PubMed ID: 16445120
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Toxicogenomics in the pharmaceutical industry: hollow promises or real benefit?
    Lühe A; Suter L; Ruepp S; Singer T; Weiser T; Albertini S
    Mutat Res; 2005 Aug; 575(1-2):102-15. PubMed ID: 15924886
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of genomic biomarkers for concurrent diagnosis of drug-induced renal tubular injury using a large-scale toxicogenomics database.
    Kondo C; Minowa Y; Uehara T; Okuno Y; Nakatsu N; Ono A; Maruyama T; Kato I; Yamate J; Yamada H; Ohno Y; Urushidani T
    Toxicology; 2009 Nov; 265(1-2):15-26. PubMed ID: 19761811
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Toxicogenomics: a pivotal piece in the puzzle of toxicological research.
    Gatzidou ET; Zira AN; Theocharis SE
    J Appl Toxicol; 2007; 27(4):302-9. PubMed ID: 17429800
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel biomarkers of acute kidney toxicity.
    Goodsaid FM; Blank M; Dieterle F; Harlow P; Hausner E; Sistare F; Thompson A; Vonderscher J
    Clin Pharmacol Ther; 2009 Nov; 86(5):490-6. PubMed ID: 19710639
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emerging applications of kinetic biomarkers in preclinical and clinical drug development.
    Turner SM; Hellerstein MK
    Curr Opin Drug Discov Devel; 2005 Jan; 8(1):115-26. PubMed ID: 15679179
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genomic and genetic biomarkers of toxicity.
    Mendrick DL
    Toxicology; 2008 Mar; 245(3):175-81. PubMed ID: 18206287
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Integrated strategies for assessment of metabolite exposure in humans during drug development: analytical challenges and clinical development considerations.
    Zhu M; Zhang D; Zhang H; Shyu WC
    Biopharm Drug Dispos; 2009 May; 30(4):163-84. PubMed ID: 19544287
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum chemical biomarkers of cardiac injury for nonclinical safety testing.
    Walker DB
    Toxicol Pathol; 2006; 34(1):94-104. PubMed ID: 16507550
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biomarkers in aquatic plants: selection and utility.
    Brain RA; Cedergreen N
    Rev Environ Contam Toxicol; 2009; 198():49-109. PubMed ID: 19253039
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A strategic view on the use of pharmacodynamic biomarkers in early clinical drug development.
    Severino ME; Dubose RF; Patterson SD
    IDrugs; 2006 Dec; 9(12):849-53. PubMed ID: 17139572
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.